View in EDS PDF Full Text

Acción de los nucleótidos en el tratamiento de la fibromyalgia.

Saved in:
Bibliographic Details
Title: Acción de los nucleótidos en el tratamiento de la fibromyalgia.
Authors: GUITART, J.1 j.guitart.boixader@gmail.com, MÁRMOL, F.2
Source: Dolor: Investigación, Clínica & Terapéutica. 2014, Vol. 29 Issue 4, p19-26. 8p.
Abstract (English): Background and objective: To evaluate the role of nucleotides in fibromyalgia (FM), a disorder that is difficult to manage, a prospective observational study was designed. Patients and method: A preparation based on nucleotides was administered for two months to 44 women who met the requirements of probable or definite FM according to the criteria of Wolfe (1994). The mean age was 55.9 ± 14 years, with an average nucleotide dosage of 10 mg of cytidine 5'-monophosphate disodium and 2,260 mg of uridine. Global self-assessment was performed at the beginning and the end of the treatment. Results: The results were positive in 17 of the 27 cases of probable FM and in 10 of the 17 cases of definite FM. The significance of the changes in the scores in the favorable cases, applying the Wilcoxon test, was p < 0.02 in the case of probable FM and p = 0.02 for definite FM. The number of cases required to find a responder was 1.7. We must highlight the good general tolerance and the virtual absence of incompatibilities and contraindications. Conclusions: These results suggest the possible utility of nucleotides for the management of FM. The fact that nucleotides, agonists of the P2X and P2Y receptors of the purinergic system, are involved in the signaling and modulation of pain pathways and in restoration and regeneration after nerve damage could explain these results, at least in part. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Fundamento y objetivo: Para evaluar la acción de los nucleótidos en la fibromialgia (FM), trastorno de difícil tratamiento, se diseñó un estudio observacional prospectivo. Pacientes y método: Se administró un preparado a base de nucleótidos durante dos meses a 44 mujeres que cumplían los requisitos de FM probable o definida, según los criterios de Wolfe (1994). La media de edad era de 55,9 ± 14 años, siendo la posología media: citidín-5'-monofosfato disódico (CMP) 10 mg y 2.260 mg de uridina en nucleótidos. Se realizó una autoevaluación global al inicio y al final, y una autoevaluación global comparativa al final del tratamiento. Resultados: Los resultados fueron favorables en 17 de los 27 casos (62,8%) de FM probable y en 10 de los 17 casos (58,8%) de FM definida. La significación de los cambios en los puntajes en los casos favorables, aplicando la prueba de Wilcoxon, fue p < 0,02 en los casos de FM probable y p = 0,02 en los de FM definida. El número de casos necesarios para hallar un respondedor fue de 1,7. Cabe destacar la buena tolerancia general y la práctica ausencia de incompatibilidades y contraindicaciones. Conclusiones: Estos resultados sugieren la posible utilidad de los nucleótidos en el manejo de la FM. El hecho de que los nucleótidos, agonistas de los receptores P2X y P2Y del sistema purinérgico, intervengan en la señalización y modulación de las vías del dolor y en la restauración y regeneración tras el daño nervioso podría explicar, en parte, estos resultados. [ABSTRACT FROM AUTHOR]
Copyright of Dolor: Investigación, Clínica & Terapéutica is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 100003419
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Acci&#243;n de los nucle&#243;tidos en el tratamiento de la fibromyalgia.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22GUITART%2C+J%2E%22&quot;&gt;GUITART, J.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;i&gt; j.guitart.boixader@gmail.com&lt;/i&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22M&#193;RMOL%2C+F%2E%22&quot;&gt;M&#193;RMOL, F.&lt;/searchLink&gt;&lt;relatesTo&gt;2&lt;/relatesTo&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Dolor%3A+Investigaci&#243;n%2C+Cl&#237;nica+%26+Terap&#233;utica%22&quot;&gt;Dolor: Investigaci&#243;n, Cl&#237;nica &amp; Terap&#233;utica&lt;/searchLink&gt;. 2014, Vol. 29 Issue 4, p19-26. 8p.
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Background and objective: To evaluate the role of nucleotides in fibromyalgia (FM), a disorder that is difficult to manage, a prospective observational study was designed. Patients and method: A preparation based on nucleotides was administered for two months to 44 women who met the requirements of probable or definite FM according to the criteria of Wolfe (1994). The mean age was 55.9 &#177; 14 years, with an average nucleotide dosage of 10 mg of cytidine 5&#39;-monophosphate disodium and 2,260 mg of uridine. Global self-assessment was performed at the beginning and the end of the treatment. Results: The results were positive in 17 of the 27 cases of probable FM and in 10 of the 17 cases of definite FM. The significance of the changes in the scores in the favorable cases, applying the Wilcoxon test, was p &lt; 0.02 in the case of probable FM and p = 0.02 for definite FM. The number of cases required to find a responder was 1.7. We must highlight the good general tolerance and the virtual absence of incompatibilities and contraindications. Conclusions: These results suggest the possible utility of nucleotides for the management of FM. The fact that nucleotides, agonists of the P2X and P2Y receptors of the purinergic system, are involved in the signaling and modulation of pain pathways and in restoration and regeneration after nerve damage could explain these results, at least in part. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Fundamento y objetivo: Para evaluar la acci&#243;n de los nucle&#243;tidos en la fibromialgia (FM), trastorno de dif&#237;cil tratamiento, se dise&#241;&#243; un estudio observacional prospectivo. Pacientes y m&#233;todo: Se administr&#243; un preparado a base de nucle&#243;tidos durante dos meses a 44 mujeres que cumpl&#237;an los requisitos de FM probable o definida, seg&#250;n los criterios de Wolfe (1994). La media de edad era de 55,9 &#177; 14 a&#241;os, siendo la posolog&#237;a media: citid&#237;n-5&#39;-monofosfato dis&#243;dico (CMP) 10 mg y 2.260 mg de uridina en nucle&#243;tidos. Se realiz&#243; una autoevaluaci&#243;n global al inicio y al final, y una autoevaluaci&#243;n global comparativa al final del tratamiento. Resultados: Los resultados fueron favorables en 17 de los 27 casos (62,8%) de FM probable y en 10 de los 17 casos (58,8%) de FM definida. La significaci&#243;n de los cambios en los puntajes en los casos favorables, aplicando la prueba de Wilcoxon, fue p &lt; 0,02 en los casos de FM probable y p = 0,02 en los de FM definida. El n&#250;mero de casos necesarios para hallar un respondedor fue de 1,7. Cabe destacar la buena tolerancia general y la pr&#225;ctica ausencia de incompatibilidades y contraindicaciones. Conclusiones: Estos resultados sugieren la posible utilidad de los nucle&#243;tidos en el manejo de la FM. El hecho de que los nucle&#243;tidos, agonistas de los receptores P2X y P2Y del sistema purin&#233;rgico, intervengan en la se&#241;alizaci&#243;n y modulaci&#243;n de las v&#237;as del dolor y en la restauraci&#243;n y regeneraci&#243;n tras el da&#241;o nervioso podr&#237;a explicar, en parte, estos resultados. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Dolor: Investigaci&#243;n, Cl&#237;nica &amp; Terap&#233;utica is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=100003419
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 19
    Titles:
      – TitleFull: Acción de los nucleótidos en el tratamiento de la fibromyalgia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: GUITART, J.
      – PersonEntity:
          Name:
            NameFull: MÁRMOL, F.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2014
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-print
              Value: 02140659
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Dolor: Investigación, Clínica & Terapéutica
              Type: main
ResultId 1